Lipella Pharmaceuticals Inc. (LIPO) — 10-Q Filings
All 10-Q filings from Lipella Pharmaceuticals Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Lipella's Q3 Loss Narrows, But Cash Dwindles Amid Zero Revenue
— Nov 14, 2025 Risk: high
Lipella Pharmaceuticals Inc. reported a net loss of $1,254,078 for the three months ended September 30, 2025, a decrease from the $1,444,637 net loss in the sam -
Lipella's Losses Widen Amid Rising R&D, Nasdaq Suspension Hits Shares
— Aug 14, 2025 Risk: high
Lipella Pharmaceuticals Inc. reported a net loss of $1,327,486 for the three months ended June 30, 2025, an increase from a net loss of $938,146 for the same pe -
Lipella Pharmaceuticals Q1 2025: Grant Revenue Soars
— May 14, 2025 Risk: medium
Lipella Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The company reported grant revenues of $179,448 for the first quarter of 2025, -
Lipella Pharmaceuticals Files Q3 2024 10-Q
— Nov 14, 2024 Risk: medium
Lipella Pharmaceuticals Inc. filed a 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the thi -
Lipella Pharmaceuticals Reports Q2 Grant Revenue
— Aug 13, 2024 Risk: medium
Lipella Pharmaceuticals Inc. filed its 10-Q for the period ending June 30, 2024. The company reported grant revenues of $103,256 for the second quarter of 2024, -
Lipella Pharmaceuticals Inc. Files 10-Q for Q1 2024
— May 9, 2024 Risk: low
LIPELLA PHARMACEUTICALS INC. (LIPO) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Lipella Pharmaceuticals Inc. filed its 10-Q report for the peri
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX